A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.

Inclusion Criteria: * ≥ 18 years old. * Histopathologically confirmed MCL expressing Cyclin D1 and/or t (11;14) chromosomal translocation.Formalin-fixed paraffin-embedded (FFPE) tissues or sections for diagnosis must be provided. It is for the approval of pathological diagnosis by the central pathology laboratory. * The patient was diagnosed with relapsed or refractory mantle cell lymphoma, and the previous treatment needs to meet the following requirements: * Failure of at least one adequate prior line of anti-CD20-containing therapy; * Failure of at least one adequate prior line of BTK inhibitor (BTKi)-containing therapy. * Failure of the last line of therapy. * At least one measurable lesion according to the Lugano 2014 criteria,. * ECOG performance status of 0-2 . Exclusion Criteria * Current or prior history of central nervous system (CNS) lymphoma. * Prior use of BCL-2 inhibitors (e.g., venetoclax/ABT-199, etc.). * Autologous stem cell transplantation or cellular therapy within 3 months prior to the first dose of ICP-248. * Prior allogeneic hematopoietic stem cell transplantation.